Abstract

Oncogenic processes exert their greatest effect by targeting regulators of cell proliferation. Studying the mechanism underlying growth augmentation is expected to improve clinical therapies. The ovarian tumor (OTU) subfamily deubiquitinases have been implicated in the regulation of critical cell-signaling cascades, but most OTUs functions remain to be investigated. Through an unbiased RNAi screen, knockdown of OTUD5 is shown to significantly accelerate cell growth. Further investigation reveals that OTUD5 depletion leads to the enhanced transcriptional activity of TRIM25 and the inhibited expression of PML by altering the ubiquitination level of TRIM25. Importantly, OTUD5 knockdown accelerates tumor growth in a nude mouse model. OTUD5 expression is markedly downregulated in tumor tissues. The reduced OTUD5 level is associated with an aggressive phenotype and a poor clinical outcome for cancers patients. Our findings reveal a mechanism whereby OTUD5 regulates gene transcription and suppresses tumorigenesis by deubiquitinating TRIM25, providing a potential target for oncotherapy.

The mechanisms by which deubiquitinases modulate tumour progression are not fully understood. Here, the authors perform an RNAi screen and identify that the deubiquitinase OTUD5 suppresses cancer growth in a TRIM25 dependent manner, which in turn controls the expression of tumour suppressor protein, PML.

Details

Title
OTUD5 cooperates with TRIM25 in transcriptional regulation and tumor progression via deubiquitination activity
Author
Li Fangzhou 1 ; Sun, Qianqian 1 ; Liu, Kun 1 ; Zhang, Ling 2 ; Lin, Ning 1 ; You Kaiqiang 3 ; Liu, Mingwei 4 ; Kon Ning 5 ; Tian, Feng 6   VIAFID ORCID Logo  ; Mao Zebin 1 ; Li, Tingting 3 ; Tong Tanjun 1 ; Qin, Jun 4 ; Gu, Wei 5 ; Li, Dawei 2   VIAFID ORCID Logo  ; Zhao, Wenhui 1   VIAFID ORCID Logo 

 Peking University Health Science Center, Department of Biochemistry and Biophysics, Beijing Key Laboratory of Protein Posttranslational Modifications and Cell Function, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
 The Affiliated Zhangjiagang Hospital of Soochow University, Center for Translational Medicine, Suzhou, China (GRID:grid.263761.7) (ISNI:0000 0001 0198 0694) 
 Peking University Health Science Center, Department of Biomedical informatics, School of Basic Medical Sciences, Beijing Key Laboratory of Protein Post-translational Modifications and Cell Function, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
 Beijing Proteome Research Center, State Key Laboratory of Proteomics, Beijing, China (GRID:grid.419611.a) (ISNI:0000 0004 0457 9072) 
 Columbia University, Institute for Cancer Genetics, and Department of Pathology and Cell Biology, College of Physicians and Surgeons, New York, USA (GRID:grid.21729.3f) (ISNI:0000000419368729) 
 Peking University Health Science Center, Department of Laboratory Animal Science, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2435937066
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.